Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

172682 items
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Pulmozyme DNase: Phase III study to start in the fall

Genentech Inc. (GNE), South San Francisco   Product: Pulmozyme DNase   Indication: Patients with chronic obstructive pulmonary disease with exacerbations requiring hospitalization   Status: Phase III study to start in the fall   ...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Company News  |  Other News

Immunex other research news

The Seattle company published its discovery of an enzyme that boosts levels of tumor necrosis factor (TNF) and its screening of enzyme inhibitors to block that action. TNF-alpha protease enzyme inhibitor (TAPI) prevents the...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Sennes Drug Innovations Inc. regulatory update

Sennes received notice of allowance for a U.S. Patent covering claims to the Senescent Derived Inhibitor protein (Sdi1), also known as p21. The Houston company said production of the protein, which is a key regulator...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Texas Biotech regulatory update

The Houston company said Immuno-Pharmaceutics Inc. has received U.S. patent No. 5,331,573, covering a supercomputer-based rational drug design technology. TXB is in the process of finalizing a letter of intent to acquire the San Diego...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Company News  |  Deals

biosys, Ecogen deal

Palo Alto-based BIOS signed a multi-year supply agreement with EECN (Langehorne, Penn.) under which BIOS will manufacture for EECN several strains of Bacillus thuringiensis, the active ingredient in EECN's product line. BIOS will provide both...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Sepracor regulatory update

SEPR received U.S. patent No. 5,331,000 covering the use of R-ketoprofen, an analgesic and antipyretic product. R-ketoprofen is a single-isomer form of ketoprofen, a non-steroidal anti-inflammatory sold in the U.S. by American Home Product Corp.'s...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Company News  |  Deals

Celltech Group deal

U.K.-based Celltech signed a letter of intent with Merck & Co. to develop and market once-daily oral compounds to treat asthma. The compounds covered in the agreement inhibit an enzyme known as phosphodiesterase IV....
12:00 AM, Jul 25, 1994  |  BC Week In Review | Company News  |  Other News

Univax news

UNVX signed a commitment letter for a $45 million project financing agreement with The BioPlex Group Inc., a financing company, to construct a complex to house the company's pilot vaccine and polyclonal antibody production plants....
12:00 AM, Jul 25, 1994  |  BC Week In Review | Company News  |  Other News

Chiron other research news

The Emeryville, Calif., company has discovered antagonists to the urokinase receptor, which are potential candidates for controlling tumor cell invasion. As published in the Proceedings of the National Academy of Sciences, the agents were found...
12:00 AM, Jul 25, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

ISIS 2105 antiviral data

ISIP announced that a trial of a single dose of the agent as an adjunct to surgical removal of warts didn't achieve statistical significance, as the recurrence rate was much lower than expected from values...

Pages